Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 1—January 2021
Research

Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France

Floriane Gallais, Aurélie Velay, Charlotte Nazon, Marie-Josée Wendling, Marialuisa Partisani, Jean Sibilia, Sophie Candon, and Samira Fafi-KremerComments to Author 
Author affiliations: Strasbourg University Hospital, Strasbourg, France (F. Gallais, A. Velay, C. Nazon, M.-J. Wendling, M. Partisani, J. Sibilia, S. Fafi-Kremer); Strasbourg University, Strasbourg (F. Gallais, A. Velay, C. Nazon, M.-J. Wendling, J. Sibilia, S. Fafi-Kremer); Rouen University Hospital, Rouen, France (S. Candon)

Main Article

Table 2

Humoral and cellular immune response to SARS-CoV-2 of COVID-19 patients and their contacts 44–102 days after symptom onset, Strasbourg, France, 2020*

ID†
Lymphocyte count, × 109/L
Days from symptom onset to sample collection
SARS-CoV-2 serologic test result
Assay results
SARS-CoV-2–specific T-cell response (no. antigens)
Biosynex Antigen: RBD of protein S

Abbott Architect Antigen: protein N (index value)
Euroimmun
Antigen: protein S (index value)
IgM
IgG
IgG
IgG/IgA
Couples with symptomatic contacts
P1 1.3 58 Pos Neg Pos Pos (3.36) Pos (2.28)/neg Pos (5)†
C1
1.8
53
Neg
Neg
Neg

Neg

Neg/neg
Pos (4)†
P2 2.0 51 Pos Neg Pos Pos (4.3) Pos (2.3)/neg Pos (7)†
C2
1.5
44
Neg
Neg
Neg

Neg

Neg/neg
Neg (1)
P4 1.6 57 Pos Pos Pos Pos (6.48) Pos (4.24)/pos (4.16) Pos (4)†
C4
1.7
51
Neg
Neg
Neg

Neg

Neg/neg
Pos (3)†
P5 1.6 68 Pos Pos Pos Pos (3.97) Pos (4.86)/pos (2.38) Pos (7)†
C5
2.0
80
Neg
Neg
Neg

Neg

Neg/neg
Pos (3)†
P7 1.3 64 Pos Pos Neg Pos (4.18) Pos (3.43)/doubtful (0.94) Pos (4)†
C7
2.2
64
Neg
Neg
Neg

Neg

Neg/neg
Neg (1)
P8 1.9 102 Pos Pos Pos Pos (7.55) Pos (5.39)/pos (9.23) Pos (5)†
C8
1.9
93
Neg
Neg
Neg

Neg

Neg/neg
Pos (4)†
Couples with asymptomatic contacts
P3 1.7 49 Pos Pos Pos Pos (8.4) Pos (7.23)/pos (3.83) Pos (8)†
C3
1.5
NA
Neg
Neg
Neg

Neg

Neg/Neg
Neg (0)
P6 2.1 69 Pos Pos Pos Pos (6.37) Pos (5.73)/pos (2.49) Pos (6)†
C6
2.2
NA
Neg
Neg
Neg

Neg

Neg/doubtful (0.85)
Neg (1)
P9 2.4 88 Pos Pos Pos Pos (7.48) Pos (7.02)/pos (5.98) Pos (6)†
C9
3.0
NA
Neg
Neg
Neg

Neg

Neg/neg
Neg (1)
P10 1.9 99 Pos Pos Neg Pos (2.46) Pos (1.75)/doubtful (0.95) Pos (5)†
C10
1.1
NA
Neg
Neg
Neg

Neg

Neg/neg
Neg (1)
P11 1.7 100 Pos Neg Pos Neg Pos (4.01)/pos (1.72) Pos (6)†
C11 1.9 NA Neg Neg Neg Neg Neg/neg Neg (0)

*In ID column, same number indicates P and C are partners in 1 couple. C, contact; ID, identification; neg, negative; P, index patient; pos, positive; PBMC, peripheral blood mononuclear cells; NA, not applicable; RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Main Article

Page created: September 29, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external